New type of drug leads to hope against resistant ovarian cancer
Scientists at USC have discovered a new type of drug for the treatment of ovarian cancer that works in a way that should not only decrease the number of doses that patients need to take, but also may make it effective for patients whose cancer has become drug-resistant.
"We need a new generation of drugs," said Shili Xu, a USC graduate student and lead author of the PNAS paper. "We need to overcome the drug-resistance issue."
The drug is a member of a new class of cytotoxic agents abbreviated as PACMA that was discovered by testing roughly 10,000 chemical compounds on cancer cells in the lab of Nouri Neamati, professor of pharmacology and pharmaceutical sciences at the USC School of Pharmacy, and a co-corresponding author of the paper.
These initial findings led to a collaboration with Nicos Petasis, co-corresponding author of the paper and professor of chemistry at the USC Dornsife College of Letters, Arts and Sciences, with appointments at the School of Pharmacy and the USC Norris Comprehensive Cancer Center of the Keck School of Medicine of USC. This joint effort led to a study of PACMA compounds that was reported last year in the Journal of Medicinal Chemistry.
In order to investigate and optimize the anticancer properties of PACMAs, co-author Alexey Butkevich, a graduate student in the Petasis lab, synthesized more than 80 newly designed compounds. One of these, called PACMA31, was eventually found to be very toxic to ovarian cancer cells and was shown to be a potentially effective drug.
In the PNAS paper, Xu and his co-authors reported that PACMA31 is a potent and selective inhibitor of a protein called Protein Disulfide Isomerase (PDI) that is highly expressed in ovarian cancer.
PACMA31 can be taken orally and accumulates in cancer cells, which means that it is less likely to cause harmful side effects in normal tissues. It is also what is known as an "irreversible" drug, meaning that it permanently latches on to its target, PDI, and refuses to wear off until the protein is degraded.
That irreversibility may result in prolonged duration of drug action that could translate into giving the patients lower doses of drugs.
"We are exploring combination studies in order to find synergy between our drug and first-line therapy for ovarian cancer," Neamati said.
Currently, there are two major types of drugs in the first-line treatment of ovarian cancer: paclitaxel, which hinders cancer cell division by inhibiting the disassembly of microtubules; and carboplatin, which binds to and causes crosslinking of DNA that results in the death of cancer cells.
PACMA31 attacks cancer cells in yet a different way, targeting PDI and thus interrupting the folding process during which proteins assume the shapes that allow them to function properly. Accumulation of misfolded proteins in a cell causes cellular stress and eventually cancer cell death.
Because PACMA31's strategy is different than that of current anticancer drugs, it has the potential to help patients who do not respond to paclitaxel or cisplatin.
"When the patient has no other choice, we could potentially treat them with our drug," Neamati said.
Other co-authors of the PNAS paper included Roppei Yamada, Yu Zhou, Bikash Debnath and Professors Roger Duncan and Ebrahim Zandi. Additional contributors to the PACMA project and co-authors to the team's first paper included Xuefei Cao, Melissa Millard, Srinivas Odde, Nick Mordwinkin, Rambabu Gundla and Professor Stan Louie.
"The discovery of this new drug and its novel mechanism of action is a great example of the power of interdisciplinary collaborations between chemists, biologists, pharmacologists and other biomedical researchers," Petasis said.
The drug will still require additional testing, but so far it appears to be nontoxic and effective at halting tumor growth. It may also have potential for treating other types of cancer, Neamati noted.
"Obviously, we think that it will go beyond ovarian cancer," he said.
Journal reference: Proceedings of the National Academy of Sciences
Provided by University of Southern California
- Researchers investigate drug resistant ovarian cancer to improve clinical treatment Aug 09, 2012 | not rated yet | 0
- Double-Duty Nanoparticles Overcome Drug Resistance in Tumors Jun 14, 2007 | not rated yet | 0
- Extracellular protein sensitizes ovarian cancer cells to chemotherapy Dec 10, 2007 | not rated yet | 0
- New treatment to overpower drug resistance in ovarian cancer Nov 15, 2010 | not rated yet | 0
- Researchers find drug duo kills chemotherapy-resistant ovarian cancer cells Dec 07, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer 17 hours ago | not rated yet | 0
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
Cancer 17 hours ago | not rated yet | 1
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
Cancer May 18, 2013 | 5 / 5 (2) | 0
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer May 17, 2013 | not rated yet | 0
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer May 17, 2013 | not rated yet | 0 |
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
5 hours ago | not rated yet | 0 |
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
5 hours ago | 5 / 5 (1) | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
6 hours ago | 5 / 5 (1) | 0 |
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
6 hours ago | 5 / 5 (2) | 0 |
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
5 hours ago | not rated yet | 0
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
10 hours ago | not rated yet | 0